COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

A Fendler, EGE de Vries… - Nature Reviews …, 2022‏ - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Q Zhang, R **ang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021‏ - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022‏ - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Y Cao, J Wang, F Jian, T **ao, W Song, A Yisimayi… - Nature, 2022‏ - nature.com
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

LA VanBlargan, JM Errico, PJ Halfmann, SJ Zost… - Nature medicine, 2022‏ - nature.com
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

PJ Halfmann, S Iida, K Iwatsuki-Horimoto, T Maemura… - Nature, 2022‏ - nature.com
The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

AA Cohen, N van Doremalen, AJ Greaney, H Andersen… - Science, 2022‏ - science.org
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health …

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

RE Chen, X Zhang, JB Case, ES Winkler, Y Liu… - Nature medicine, 2021‏ - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

KM Hastie, H Li, D Bedinger, SL Schendel… - Science, 2021‏ - science.org
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

BE Jones, PL Brown-Augsburger, KS Corbett… - Science translational …, 2021‏ - science.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …